News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Empowered Funds LLC increased its stake in Insmed, Inc. (NASDAQ:INSM) by 32.6% in the first quarter, owning 51,986 shares worth $8.5 million. Several other institutional investors also increased their holdings in Insmed during the same period, while company insiders made significant stock sales. Analyst …
Darwin Global Management, Ltd., along with its Chief Investment Officer Dr. Abhishek Trehan and Darwin Global Master Fund Ltd., has reported a beneficial ownership of 3.0% in Insmed Inc. common stock, totaling 6,431,163 shares. This stake is based on 216,752,451 shares outstanding as of …
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm is encouraging shareholders of TransMedics Group to visit its website or contact them for more information regarding …
Allison Transmission insider Eric Scroggins sold 1,050 shares of the company's stock for $131,250 on August 11th, reducing his direct ownership by 5.95%. This sale follows strong quarterly results where Allison reported EPS of $2.73, exceeding estimates, and revenue growth of 92.4% year-over-year. Analysts …
An officer at Insmed (INSM.US) recently sold a significant amount of common stock, totaling US$31.96 million. This transaction highlights an insider trading activity, which can sometimes be viewed by investors as a signal regarding the company's future prospects or valuation.
Insmed (INSM) saw its stock rise 34.2% following a significant reduction in its net loss for Q2 2026, narrowing to US$13.24 million from US$321.69 million a year prior. This improvement in financial performance, along with reiterated revenue guidance for its key drugs BRINSUPRI and …
Wasatch Advisors LP reduced its stake in TransMedics Group (NASDAQ:TMDX) by 10.9% in the second quarter but still holds 308,434 shares valued at $20.49 million. The company's recent earnings showed a revenue beat but an EPS miss, leading to mixed analyst ratings with an …
The average 12-month price target for Allison Transmission Holdings, Inc. stock has increased to $144.14 from $138.78, according to 7 analysts, suggesting a 17% potential upside from its August 12 closing price. The consensus rating from 10 analysts remains "Buy," with 5 Buy and …
Insmed (NASDAQ:INSM) COO Roger Adsett sold 239,850 shares of the company's stock for approximately $32.0 million, reducing his direct holdings by over 70%. Despite the sale and a slight dip in stock price, Insmed reported better-than-expected quarterly revenue and adjusted loss per share. Analyst …
Insmed Chief Operating Officer Roger Adsett sold 98,744 shares of common stock at a weighted average price of $133.27 per share, totaling over $31 million. Following this transaction, Adsett directly owns 98,744 shares. This information is based on an SEC Form 4 filing.
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Allison Transmission Holdings stock has quietly put up very strong multi year returns, and at around US$124.99 per share it still screens as undervalued on broader valuation …
Allison Transmission Holdings, Inc. (NYSE:ALSN) has declared a quarterly dividend of $0.29 per share, payable on August 31st to shareholders of record on August 21st. This dividend represents an annualized payout of $1.16, yielding 0.9%, and is well-covered by the company's earnings with an …
Allison Transmission Holdings Inc. has declared a cash dividend of $0.29 per share for the third quarter of 2026. The dividend is payable on August 31, 2026, to shareholders of record as of August 21, 2026. Future dividends are subject to the discretion of …
Amundi significantly reduced its stake in Allison Transmission Holdings, Inc. by selling 296,664 shares, representing a 98.9% decrease in its holdings. Despite this, other institutional investors like Jane Street Group LLC and Goldman Sachs Group Inc. increased their positions in the company. Allison Transmission …
This article lists various Exchange Traded Funds (ETFs) that hold stocks of TransMedics Group, Inc. The ETFs are primarily small-cap and health technology focused, providing investors with diversified exposure to the company. The list includes details such as market value, weight of TransMedics stock, …
Sharemaestro market context Price below Trend Line 52 weeks -32.1% · Next-week setup positive 56.0%Allison Transmission Holdings Inc. (NYSE:ALSN) announced a cash dividend of $0.29 per share for the third quarter of 2026, payable on August 31, 2026, to stockholders of record by August 21, 2026. The company, a manufacturer of mobility and work solutions, stated that future …
Allison Transmission Holdings, Inc. announced that it will maintain its quarterly dividend at $0.29 per share. This dividend is payable on August 31 to shareholders of record as of August 21. The announcement was made on August 11, 2026, at 05:33 pm EDT.
INDIANAPOLIS, Aug. 11, 2026 /PRNewswire/ -- Allison Transmission Holdings Inc. (NYSE: ALSN), a global leader in high-performance mobility and work solutions built for the needs of the modern industrial world, announced today that its Board of Directors has declared a cash dividend of $0.29 …
A holder of Allison Transmission Holdings Inc. (ALSN) common stock plans to sell 1,050 shares through Merrill Lynch on the NYSE. These shares, valued at $131,250.00, were acquired on February 28, 2024, from the vesting of a performance share unit award. The planned sale …
TransMedics Group, Inc. (TMDX) presented a strong, vertically integrated organ transplant platform demonstrating significant financial growth. The company outlined four major expansion initiatives and a clear strategy to achieve $2–$3 billion in revenue, driven by strategic investments in technology, logistics, and new markets. These …
The biotechnology stock’s 52-week weekly chart shows a sharp advance, but trend confirmation and relative-strength readings remain mixed.
H.C. Wainwright has reiterated a Buy rating on Insmed (NASDAQ:INSM) stock with a $220 price target, driven by the strong performance of its drug Brinsupri. Brinsupri's revenue growth exceeded expectations, with the company raising its 2026 revenue guidance for the drug to $1.25 billion …
Assenagon Asset Management S.A. has acquired a new position in Allison Transmission Holdings, Inc. (NYSE:ALSN), purchasing 100,489 shares valued at approximately $11.3 million, giving them a 0.12% stake. Institutional investors collectively own 96.90% of the company, which recently reported strong quarterly earnings, beating EPS …
An SEC Form 144 filing by INSMED Inc. indicates a potential sale of 239,850 common shares, with an indicated trading date of August 10, 2026, on NASDAQ. The filing also discloses prior sales by Roger Adsett, including 2,370 shares on June 3, 2026, and …
Allison Transmission Holdings, Inc. reported strong Q2 2026 results with US$1,566 million in sales and US$181 million in net income, while also raising its full-year 2026 guidance to US$5,800 million - US$6,000 million in sales and US$600 million - US$700 million in net income. …
Allison Transmission Holdings Inc. (ALSN) has scheduled a Form 144 sale of 3,961 shares of its common stock. These shares are to be issued upon the exercise of employee stock options and will be sold in a broker-assisted cashless transaction through Merrill Lynch on …
JPMorgan Chase & Co. has lowered its price target for Insmed (NASDAQ:INSM) to $175.00 from $179.00, while maintaining an "overweight" rating. This adjustment comes despite Insmed exceeding quarterly earnings expectations, reporting a loss of $0.06 per share against a forecasted $0.67 loss and a …
Insmed (NASDAQ: INSM) has significantly outperformed the market over the last five years, with an annualized return of 41.43%. An initial investment of $1000 made five years ago would now be worth $5,573.37. This demonstrates the powerful effect of compounded returns on investment growth.
The biotechnology stock closed at 131.10 USD, with short-term momentum improving even as trend confirmation and relative strength remain weak.
Search by ticker symbol or company name and select a result to open its chart.